Expected values for gastrointestinal and pancreatic hormone concentrations in healthy volunteers in the fasting and postprandial state
Annals of Clinical Biochemistry
MetadataShow full item record
Meek, C., Lewis, H., Burling, K., Reimann, F., & Gribble, F. (2020). Expected values for gastrointestinal and pancreatic hormone concentrations in healthy volunteers in the fasting and postprandial state. Annals of Clinical Biochemistry https://doi.org/10.1177/0004563220975658
Background: Gastrointestinal hormones regulate intestinal transit, control digestion, influence appetite and promote satiety. Altered production or action of gut hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), may contribute to the biological basis of obesity and altered glucose homeostasis. However, challenges in analytical methodology and lack of clarity on expected values for healthy individuals has limited progress in this field. The aim of this study was to describe expected concentrations of gastrointestinal and pancreatic hormones in healthy volunteers following a standardised meal test (SMT) or 75g oral glucose tolerance test (OGTT). Methods: 28 healthy volunteers (12 men, 16 women; mean age 31.3 years; mean body mass index 24.9 kg/m2) were recruited to attend a hospital clinic on two occasions. Volunteers had blood sampling in the fasting state and were given, in randomised order, an oral glucose tolerance test (OGTT) and standardised mixed liquid meal test with venepuncture at timed intervals for 4 hours after ingestion. Analytical methods for gut and pancreatic hormones were assessed and optimised. Concentrations of gut and pancreatic hormones were measured and used to compile ranges of expected values. Results: Ranges of expected values were created for glucose, insulin, glucagon, GLP-1, GIP, PYY and free fatty acids in response to a standardised mixed liquid meal or OGTT. Intact Proinsulin and C-peptide levels were also measured following the OGTT. Conclusions: These ranges of expected values can now be used to compare gut hormone concentrations between healthy individuals and patient groups.
This research was funded by the Wellcome Trust (WT084210Z/07/Z and WT088357Z/09/Z) and the MRC (MRC_MC_UU_12012/3). CLM is supported by the Diabetes UK Harry Keen Intermediate Clinical Fellowship (DUK-HKF 17/0005712) and the EFSD-Novo Nordisk Foundation Future Leader’s Award (NNF19SA058974). This research was supported by the NIHR Cambridge Clinical Research Facility.
Diabetes UK (17/0005712)
Novo Nordisk Foundation (NNF19SA058974)
WELLCOME TRUST (106262/Z/14/Z & 106263/Z/14/Z)
External DOI: https://doi.org/10.1177/0004563220975658
This record's URL: https://www.repository.cam.ac.uk/handle/1810/312528
All rights reserved